Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles:
Related suggestion:
3 armed drones downed near U.S. military base in northern IraqBiden touts progress on economy, immigration despite wide disapprovalFishermen spot boat with 20 corpses floating off the coast of northeastern Brazil, reports sayBiden touts progress on economy, immigration despite wide disapprovalIAEA chief stresses further monitoring of Fukushima nuke wastewater dischargeReinhart gets his 55th goal to win it, Florida tops Buffalo 3California sees rise in tuberculosis casesIraq, U.S. resume dialogue on ending U.S.UN asks Houthis to reconsider order to expel U.S., British nationalsCoronel has 3 saves, first shutout of season, Red Bulls and Fire tie 0
3.9833s , 6500.328125 kb
Copyright © 2024 Powered by Medicare can pay for obesity drugs like Wegovy in certain heart patients ,Global Gateway news portal